Information Provided By:
Fly News Breaks for June 27, 2017
VRX
Jun 27, 2017 | 15:05 EDT
Wells Fargo analyst David Maris noted that several Valeant products are included on the FDA's list of branded drugs that have no listed patents or exclusivities and for which the agency has yet to approve an abbreviated new drug application. The FDA said it intends to expedite the review of any generic drug application for a product on this list, which Maris feels is a risk about which Valeant investors should be aware. He keeps an Underperform rating on Valeant shares.
News For VRX From the Last 2 Days
There are no results for your query VRX